By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Veloxis Pharmaceuticals A/S 

Kogle Allé 4

  DK-2970  Hørsholm  Denmark
Phone: 457-033-3300 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® Receives European Marketing Authorization For Treatment Of Both Kidney And Liver Transplant Patients 7/28/2014 7:44:37 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:32:36 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:06:09 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014 10:50:42 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Senior Level Appointments In Preparation For U.S. Commercialization Of Envarsus® XR (Tacrolimus Extended-Release Tablets) 6/4/2014 9:05:48 AM
Veloxis Pharmaceuticals A/S (VELO) Receives Positive Opinion From CHMP For Envarsus® For Treatment Of Both Kidney And Liver Transplant Patients 5/22/2014 9:25:27 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Warrant Programme - New Articles Of Association 5/22/2014 9:23:04 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Three Months Of 2014 5/15/2014 6:18:41 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Three Months Of 2014 5/14/2014 11:21:58 AM
Veloxis Pharmaceuticals A/S (VELO) To Host Conference Call Announcing Interim Report For First Quarter 2014 – Results From 1 January To 31 March, 2014 5/6/2014 9:17:37 AM
1234567
//-->